This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

Alzheimer’s Disease Therapeutics: Alternatives to Amyloid

Alzheimer’s Disease Therapeutics: Alternatives to Amyloid

Tuesday, December 11, 2018, 9:00 AM - 6:00 PM

The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York

Presented By

The New York Academy of Sciences

The Brain and Behavior Discussion Group

 

For years, the Alzheimer’s research community has been focused on amyloid as the key to curing this devastating disease.  However, there are currently only four drugs approved to treat the symptoms of Alzheimer’s disease, and no new therapies have been approved in the last 15 years.  Moreover, multiple clinical trials have recently failed, including several Phase III trials that targeted amyloid with antibodies.  As a result, there is burgeoning interest in identifying alternative drug targets: over half of ongoing preclinical research in Alzheimer’s disease now focuses on pathways other than amyloid and tau.

This one-day symposium will highlight emerging mechanisms driving Alzheimer's disease — including mitochondrial factors, the vascular system, infections, and autophagy — as well as discuss strategies to identify new therapeutic targets.

Call for Abstracts

Abstract submissions are invited for a poster session. For complete submission instructions, please visit our online portal. The deadline for abstract submission is Friday, October 12, 2018.

Registration

Member
$60
Nonmember Academia, Faculty, etc.
$105
Nonmember Corporate, Other
$160
Nonmember Not for Profit
$105
Nonmember Student, Undergrad, Grad, Fellow
$70
Member Student, Post-Doc, Fellow
$25

Scientific Organizing Committee

Alzheimer’s Disease Therapeutics: Alternatives to Amyloid
Howard Fillit, MD,
Alzheimer's Drug Discovery Foundation
Nell Rebowe
Nell Rebowe,
Anavex Life Sciences
Alzheimer’s Disease Therapeutics: Alternatives to Amyloid
Rudolph Tanzi, PhD,
Harvard Medical School
Alzheimer’s Disease Therapeutics: Alternatives to Amyloid
George Zavoico, PhD,
B. Riley FBR
Alzheimer’s Disease Therapeutics: Alternatives to Amyloid
Sara Donnelly, PhD,
The New York Academy of Sciences
Alzheimer’s Disease Therapeutics: Alternatives to Amyloid
Sonya Dougal, PhD,
The New York Academy of Sciences
Alzheimer’s Disease Therapeutics: Alternatives to Amyloid
Amanda Sadacca, PhD,
The New York Academy of Sciences

Speakers

Ana Maria Cuervo
Ana Maria Cuervo, MD, PhD,
Albert Einstein College of Medicine
Alzheimer’s Disease Therapeutics: Alternatives to Amyloid
Howard Fillit, MD,
Alzheimer's Drug Discovery Foundation
Paula Grammas
Paula Grammas, PhD,
University of Rhode Island
Alzheimer’s Disease Therapeutics: Alternatives to Amyloid
Jacob Hooker, PhD,
Harvard Medical School
Xavier Langlois
Xavier Langlois, PhD,
Abbvie
Alzheimer’s Disease Therapeutics: Alternatives to Amyloid
Christopher Missling, PhD,
Anavex Life Sciences
Robert Moir
Robert Moir, PhD,
Harvard Medical School
Alzheimer’s Disease Therapeutics: Alternatives to Amyloid
Rudolf Tanzi, PhD,
Harvard Medical School
Eugenia Trushina
Eugenia Trushina, PhD,
Mayo Clinic